azn201507286k.htm



FORM 6-K


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of  July 2015

 
Commission File Number:  001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X            Form 40-F  __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  __                 No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):   82-_____________

 
 
AstraZeneca Half Year Results 2015
 
Tomorrow, Thursday, 30 July 2015, AstraZeneca will release half year results for 2015 at 07:00 bst.
 
An analyst presentation of the half year results will take place at 12:00 bst and will be accessible by a choice of two routes:
 
Audio webcast
 
The presentation will be available to download on the AstraZeneca Investor Relations website http://www.astrazeneca.com/investors 15 minutes before the analyst presentation begins.
 
 
Teleconference with Q&A.  Dial in numbers:
 
UK (freephone):               0800 694 2370 
International:                   +44 (0) 1452 557 749    
Sweden (freephone):       0200 883 079
US (freephone):               1 866 977 7645 
 
Conference ID:75191806
 
Details of the teleconference and webcast replay facilities are available on the Investor Relations section of the AstraZeneca website http://www.astrazeneca.com/investors.
 

SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC




Date: 29 July 2015
By:  /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary